Alterity Therapeutics (ASX:ATH) Total Operating Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.56
View Full Analysis

What is Alterity Therapeutics Total Operating Expense?

Alterity Therapeutics ASX:ATH -1.75% 34 Total Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 34/100.

Alterity Therapeutics's Total Operating Expense for the three months ended in Dec. 2025 was A$0.00 Mil. Alterity Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Alterity Therapeutics Total Operating Expense Related Terms

Alterity Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Total Operating Expense Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.74 15.14 14.37 19.40 12.33

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Total Operating Expense of A$0.00 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Total Operating Expense too high?
Alterity Therapeutics' current Total Operating Expense is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Total Operating Expense compare to VRTX and REGN?
Alterity Therapeutics' Total Operating Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Total Operating Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Total Operating Expense of A$0.00 Mil. The current Total Operating Expense is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Total Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price